Author: Mark

Immunoglobulin (IG) has long been a specialized area within pharmacy, yet it continues to influence the broader market. As such, it’s important for pharmaceutical professionals to maintain at least a basic understanding of its role and impact. Today’s article offers a deep dive into increasingly turbulent IG waters.

In recent years, the landscape for immunoglobulin (IG) therapies – both intravenous (IVIG) and subcutaneous (SCIG) – has seen a wave of new entrants and formulations. While this offers important opportunities for improved treatment options, it also brings a suite of issues that pharmaceutical companies, specialty pharmacies, and clinicians need to navigate carefully.

1. Indication and differentiation complexity
   One major issue is that each IG product has a slightly different approved indication set. As noted in the article, “no one Ig product has all 7 indications.” For pharma companies, the differentiation of new IG products (in terms of indication, concentration [e.g., 10 % vs 5 %], route of administration, stabilizers or excipients) becomes critical—both to claim a niche and to avoid confusion in the marketplace. Hence, strategy around label expansion, off-label usage, and lifecycle management becomes more complex.
2. Supply-chain & raw-material bottlenecks
   IG therapies are inherently dependent on human plasma donation, pooling thousands of donors, with rigorous viral-inactivation and fractionation processes. Demand for IG continues to grow strongly, yet the supply chain remains fragile. For example, the rising demand outstrips production capacity, creating potential shortages and price instability. For manufacturers and supply-chain teams, this means investing in donor centers, securing long-term contracts, and implementing risk mitigation (e.g., alternate sites, geographic diversification).
3. Regulatory & reimbursement pressures
   As IG products expand beyond classical primary immunodeficiency (PID) into autoimmune or neurologic indications, regulators and payers are scrutinizing the evidence base and value proposition. From a pharma perspective, this means that new IG launches must plan for rigorous clinical data, real-world evidence collection, and robust health-technology-assessment (HTA) strategies, especially when positioning new formulations or routes.
4. Product switching and patient transition issues
   With multiple IG brands and new entrants, there are operational challenges in switching patients from one IG product to another (for example when a new formulation is launched, or a payer mandates a change). Patient-and-physician reassurance, monitoring of tolerability and efficacy, and managing logistics (e.g., home infusion set-up) are all non-trivial.
5. Market‐access and cost pressure
   Given the high unit cost of IG therapies, the arrival of new products often raises questions of pricing, rebate strategies, and access. Manufacturers must balance premium positioning (e.g., higher concentration, faster infusion) with payer demands for cost containment and formulary space.

For pharma industry professionals, these five issue areas – indication differentiation, supply chain, regulatory/reimbursement, switching logistics, and market access/cost – represent the top strategic imperatives when launching or managing new IG products.

---

A Deeper Dive into the New IG Products

CLICK HERE to read the full article

Yeah, Yeah….
The message from the article below is preaching to the choir… but this hymn can’t be sung enough.

The central message in this article is that pharmaceutical manufacturers are increasingly relying on “limited-distribution drug (LDD) networks” as a key channel strategy—and that providers seeking to participate must adopt a proactive posture early on to gain access. Specialty pharmacies and provider partners must anticipate and demonstrate the kinds of capabilities manufacturers are now demanding.

Key points for management:

1. Why LDD networks matter: Manufacturers restrict distribution of certain high-cost, high-complexity therapies to a select network of pharmacies and distribution partners in order to maintain tighter control over clinical support, patient outcomes, data capture and risk-management.
2. What manufacturers look for: To be part of an LDD network, pharmacies/partners must showcase robust clinical infrastructure (disease-state expertise, adherence programs), strong data and reporting systems, national accreditations, payer-contracting strength and service models that align with the manufacturer’s goals.
3. What proactive means in practice: Rather than waiting for outreach, provider partners should conduct a “self-assessment” of readiness in those domains, articulate their unique value-proposition (e.g., rare disease specialty, high treatment-touch model), build relationships with manufacturers and internal teams, and present themselves as an extension of the manufacturer’s strategy rather than simply a dispensing partner.
4. Implications for life sciences: For manufacturers, the article suggests careful calibration of network size and partner criteria; for provider organizations, it highlights the competitive nature of gaining LDD network slots and the fact that access can be a differentiator in market strategy.
5. Bottom line: The era of open, commoditized distribution is fading for many specialty therapies. Success now requires alignment of clinical, operational and strategic capabilities—and readiness to demonstrate those proactively.

For life-sciences executives, the takeaway is clear… when planning launch and access strategies for specialty therapies, embed consideration of network partner readiness early and treat LDD network selection as a strategic tool—not an after-thought.

---

Being Proactive a Key to Gaining LDD Network Entry

CLICK HERE to read the full article

The FDA recently approved a new ORAL therapy, Jascayd (nerandomilast) from Boehringer Ingelheim, indicated for idiopathic pulmonary fibrosis (IPF) in adult patients. IPF is a rare, progressive disease with no cure and limited treatment options. No other therapy has been approved for IPF in more than a decade.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, deadlier than several common cancers, with most patients dying within five years of diagnosis. It mainly affects adults over 50, especially men, and is marked by symptoms such as persistent cough and shortness of breath. The cause is unknown, and about 200,000 people in the U.S. are affected.

CLICK HERE to access prescribing information

The company confirmed the list price of Jascayd at $16,219 per month.

The company did not announce plans for logistics /distribution. Given that it is an ultra-rare, high-cost oral therapy it is strongly felt that Jascayd will be available via specialty pharmacy limited distribution.

---

FDA approves drug to treat idiopathic pulmonary fibrosis

CLICK HERE to read the company press release

Amid what some would call chaos in the halls of the FDA, HHS, etc., some light came shining through recently. The FDA announced a new collaborative approach to a procedural pathway called Rare Disease Evidence Principles (RDEP) targeted at ultra-rare genetic diseases. Under RDEP, drugs and biologics that meet defined criteria may engage earlier with FDA’s review teams to pre-negotiate what evidence can support a “substantial evidence of effectiveness” determination. FDA is signaling that it will more explicitly consider nontraditional evidence (e.g., single-arm trials, external control arms, natural history studies).

Eligibility for the RDEP pathway is limited and sponsors must meet specific requirements:

• address a known inborn genetic defect whose dysfunction is a principal driver of disease;
• target a very small patient population (often < 1,000 in the U.S.);
• treat a disease with severe progressive deterioration (rapid disability or mortality);
• have no adequate alternative therapies; and
• directly correct or replace the defective gene or protein.

Once accepted, sponsors may benefit from a meeting with FDA to agree on required evidence and clarify what confirmatory or supportive data the agency will accept. However, post-marketing obligations may increase for products approved under RDEP.

For pharmaceutical manufacturers, key issues include:

• Strategic planning: early determination whether a therapy qualifies for RDEP and timing of the meeting request.
• Trial design flexibility: need to justify use of single-arm designs, external/natural history controls, or novel endpoints in lieu of large, randomized trials.
• Regulatory risk: despite flexibility in evidence considerations, the “substantial evidence” legal standard remains unchanged, so the burden of persuasion stays high.
• Post-approval commitments: increased post marketing study or monitoring obligations.

Opportunities include:

• Faster, more efficient development pathways, with earlier regulatory clarity.
• Reduced trial size and burden where patient recruitment is inherently constrained.
• Enhanced collaboration possibilities with FDA — sponsors can negotiate evidence expectations up front, reducing uncertainty.
• Differentiation and leadership in gene therapy / rare disease portfolio development, especially for biopharma firms with relevant platforms.

---

New FDA approval process promotes development of rare disease gene therapies

CLICK HERE to read the full analysis

Cigna’s Evernorth Health Services is making a bold move in the specialty pharmacy space with a $3.5 billion investment in Shields Health Solutions. The deal comes on the heels of Sycamore Partners’ $10 billion acquisition of Walgreens, which carved Shields into a standalone company. The question remains….Is this price a wise investment for Evernorth?

Expanding a Strategic Footprint
Evernorth already commands significant scale through Express Scripts and Accredo, serving patients with complex therapies and infusion needs. Shields adds a new dimension: deep integration with health systems. With 80+ partnerships spanning more than 1,000 hospitals and clinics nationwide, Shields gives Evernorth a golden key to these provider networks, a critical differentiator as care delivery becomes increasingly fragmented across home, clinic, and hospital settings.

The Specialty Cost Imperative
Specialty drugs, from hepatis C to cell & gene therapies, now account for well over half of prescription spending in the US. Employers and payers report specialty costs consuming 60% or more of total drug budgets, making them the single biggest driver of pharmacy spend. This reality underscores why specialty pharmacy isn’t just a growth area… it’s the battleground for cost, access, and value in U.S. healthcare…. and large health systems have real leverage with manufacturers enabling access to even the highest cost, limited access drugs.

What It Means for the Market
Evernorth’s bet on Shields reflects a larger trend: integration across the pharmacy, payer, and provider landscape. As more high-cost therapies reach the market, the companies best positioned to manage specialty spend will be those that can control distribution channels, deliver clinical support, and align with health systems. Suddenly, $3.5 billion starts to look like a bargain price.

---

Cigna’s Evernorth Invests $3.5 Billion In Specialty Pharmacy Formerly Owned By Walgreens

CLICK HERE to read the article

The FDA recently approved a new sub-q therapy, Dawnzera (donidalorsen) from Ionis Pharmaceuticals, Inc. indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older. Dawnzera is the first and only RNA-targeted medicine approved for HAE, designed to target plasma prekallikrein (PKK), a key protein that activates inflammatory mediators associated with acute attacks of HAE. Dawnzera was designed to target plasma prekallikrein, a protein that activates inflammatory mediators associated with acute attacks of HAE.

Dawnzera represents a first-in-class therapy for hereditary angioedema (HAE), offering a new approach to disease management. This subcutaneous treatment is designed to be self-administered, providing greater convenience for patients. According to Ionis, Dawnzera’s ease of use and self-administration make it a preferred prophylactic option for many individuals living with HAE.

Dawnzera has demonstrated the ability to reduce sudden and often unpredictable flareups that characterize HAE of severe swelling affecting the limbs, the face and other bodily areas. HAE affects 7,000 people in the U.S. and can be fatal resulting from restricted airways.

It is reported that the cost of Dawnzera will be $57,462 per dose or $747,000 annually based on the maximum dosing (q4 week) schedule.

Dawnzera will be available through specialty pharmacy distribution. Orsini Specialty Pharmacy has been selected as the exclusive SP partner for Dawnzera.

CLICK HERE to access prescribing information

---

DAWNZERA (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

CLICK HERE to read the company press release

Manufacturers of rare disease and specialty products in the U.S. face an increasingly intricate distribution landscape. What once looked like a relatively simple path from drug to patient now demands strategic alignment across state and federal compliance, logistics models, and evolving legislation that threatens to upend established networks.

The article we are spotlighting today opens the curtain to see several key emerging challenges for Pharma. A full read of the article will add significant color to this short summary Report.

State Licensure Regimes & Virtual Distribution Risks
Each U.S. state (and D.C.) enforces its own licensing rules for drug distributors, creating significant burdens for national operations. Many states now extend these requirements to “virtual distributors” that transfer title or broker products without physical facilities, meaning even remote or non-handling manufacturers may still need state licensure.

Distribution Models as Compliance Tools
To mitigate state licensing burdens, manufacturers are exploring variants of 3PL and title transfer models each carrying trade-offs in cost, control, regulatory risk, and operational complexity:

• A “flash title” model transfers ownership to a 3PL briefly to satisfy state licensing rules, though the 3PL may not perform storage or distribution.
• A full 3PL title model transfers both title and possession to the logistics provider, allowing the manufacturer to outsource licensure burdens to that party.

State-Level Network Restrictions & Limited Distribution Network Pressures
States are tightening oversight of “limited distribution networks” (LDNs) even prohibiting manufacturers from restricting distribution to out-of-state pharmacies without offering comparable local access or board-approved justification. Specialty drug makers relying on LDNs must monitor such laws and prepare for penalties.

Federal Healthcare Compliance Layers
Beyond state hurdles, any arrangement with 3PLs or distributors must respect Anti-Kickback rules and government price reporting obligations. Manufacturers must properly assess and document fair market value (FMV) for services rendered, especially when using novel title/3PL structures, to avoid kickback or overpayment risks.

For Pharma manufacturers in the rare/specialty segment, each drug’s distribution strategy must now be as carefully governed as its clinical strategy.

---

Rare Disease and Specialty Product Manufacturers: Distribution Model Considerations

CLICK HERE to read the full article

The FDA recently approved Papzimeos (zopapogene imadenovec-drba), a new therapy from Precigen Inc., for the treatment of adults with recurrent respiratory papillomatosis (RRP). This marks the first and only approved therapy available for the rare condition.

RRP is a debilitating and sometimes life-threatening disease caused by chronic infection with HPV types 6 or 11. The infection leads to recurrent benign tumors, or papillomas, within the respiratory tract. While typically noncancerous, papillomas consist of abnormal epithelial cell growths that can obstruct airways and require repeated surgical interventions.

RRP affects an estimated 27,000 adults in the United States, highlighting the unmet need for effective treatment options. Until now, patients have relied primarily on repeated surgical procedures to manage symptoms.

According to Precigen, Papzimeos published a defined dosing schedule: patients receive treatment on day one, followed by another dose at week two, and then once every four weeks thereafter. The therapy is supplied as a frozen suspension for subcutaneous injection. Prescribing information states that the therapy be rapidly thawed and immediately administered. Given the complexity of the disease, need for close monitoring, and preparation & handling, administration will take place in a specialist’s office.

Precigen has announced a list price of $115,000 per vial, totaling approximately $460,000 for the first twelve-week course of treatment.
Distribution and logistics details have not yet been disclosed.

CLICK HERE to access prescribing information

---

Precigen Announces Full FDA Approval of Papzimeos (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

CLICK HERE to access the press release

In the ever-evolving landscape of specialty pharmaceuticals, affordability and access remain front and center for patients, payers, and pharmacies alike. MedImpact Holdings Inc. is now poised to make a significant stride in this arena with the announcement of direct access to an unbranded biosimilar version of ustekinumab-aekn, a lower-cost alternative to the well-known reference drug, Stelara.

Breaking Down the Announcement
MedImpact’s new biosimilar will be distributed by Anda, affiliated with Teva Pharmaceuticals USA, Inc., and available for purchase from Birdi, Inc., MedImpact’s preferred partner. Most importantly, any licensed specialty pharmacy will have access to this product, potentially opening the door to wider market competition.

It is well known that a drug’s cost rises at each step in the supply chain. By adopting an unbranded strategy, MedImpact aims to bypass traditional markups and inefficiencies that inflate prices along the journey from manufacturer to patient. The program will provide specialty pharmacies with a new sourcing channel… not just MedImpact clients… more choice and control over their pharmacy benefit spending.

The model is also about transparency. Moving away from convoluted rebate structures and towards clear, upfront pricing gives payers and members access to true costs when the medication is dispensed.

Will this program start a sea change in the marketplace? MedImpact’s move is more than just another product launch… it’s a signal of changing tides in specialty pharmacy, where value, choice, and transparency are fast becoming the new standard. The availability date for the unbranded ustekinumab-aekn biosimilar is January 01, 2026.

---

MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US

CLICK HERE to read the full press release

We are all aware that orphan disease drugs are typically very expensive. Yet, health plans tend to avoid risk-sharing arrangements that could significantly mitigate those costs. Reluctance stems from diverse factors such as the differences in dosing schedules (daily vs. weekly, etc.), administration routes (provider- vs. patient-administered), and tolerability issues, etc. Collectively, the abundant variables of each unique course of treatment create significant barriers to implementing and tracking risk contract performance.

But, the landscape is changing. Between 2020 and 2024, roughly 20-25 new orphan drugs gained FDA approval annually, with projections indicating 160-200 more could enter review by 2030. Many of these new treatments include gene and cell therapies, biologics, and high-cost small molecules for the same conditions. This increasing pipeline will likely lead to multiple high-priced options competing for the same orphan indication, intensifying market competition.

As more therapies emerge for the same conditions, will pricing pressures curb future growth, especially if new treatments do not demonstrate significant clinical benefits? To justify premium pricing amid stiff competition, later entrants might consider risk-sharing contracts, especially if they can substantiate clinically meaningful advantages.

Can risk contracting be that key differentiator? Risk contracts are particularly appealing when clinical data support superior outcomes, enabling companies to justify higher prices. Such contracting aligns well with the rising emphasis on value-based care in managed health plans and presents a strategic opportunity for new entrants to position themselves as committed to delivering that value.

With an expanding pipeline, building risk-sharing arrangements into drug launch strategies could be a necessity for orphan drug developers… provided they can minimize operational burdens on payers.

---

Risk Contracting When Orphan Disease Space is Crowded

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative pricing strategies.

CLICK HERE to read the full article